Similar to hormone replacement therapy clinical trials [6], our previous work found a marked upregulation of MMP2 expression with increased aggressiveness of NSCLC cells induced by estrogen and the activation of ERβ [13]. The gene discussed is MMP2; the disease is non-small cell lung carcinoma.